Xellia Pharmaceuticals will manufacture essential antibiotics for Civica Rx.
Civica Rx and Xellia Pharmaceuticals have announced a partnership wherein Xellia will manufacture two anti-infective antibiotic medications that are routinely in short supply. Xellia will manufacture vancomycin and daptomycin for Civica’s member health systems.
Civica was established in 2018 to combat chronic generic drug shortages, and is aiming to stabilize the supply of antibiotics, anesthetics, cardiac medications, pain management medications, and other essential sterile injectable medications through a three-pronged product supply strategy.
Xellia, headquartered in Copenhagen, Denmark, produces its own active pharmaceutical ingredients and finished injectable drug products for serious and often life-threatening bacterial and fungal infections. With this new agreement, the company is expanding its manufacturing and sales capabilities within the United States.
Xellia is the first of several generic drug manufacturers who hope to collaborate with Civica. The company, formed by a number of health systems across the United States, expects to partner with other manufacturers that have FDA-approved manufacturing facilities with the capacity to provide the amount of generic drugs Civica will need for its member systems. Civica says that it will be developing and acquiring abbreviated new drug applications (ANDAs) for generic drugs and working with contract manufacturing organizations to produce the medications, as well as acquiring and building Civica manufacturing facilities using these ANDAs.